William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform from Market Perform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals Announces CARDINAL Trial Data Presentation
- Terns Pharmaceuticals announces data from CARDINAL trial of TERN-701
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Terns Pharmaceuticals price target lowered to $15 from $20 at Citizens JMP
- Cautious Hold on Terns Pharmaceuticals Amid Underwhelming Trial Results and Strategic Shift